Showing 3231-3240 of 5646 results for "".
- Inovio’s COVID-19 Vaccine Candidate INO-4800 Hit by FDA Partial Holdhttps://modernod.com/news/inovios-covid-19-vaccine-candidate-ino-4800-hit-by-fda-partial-hold/2478341/Inovio Pharmaceuticals said that the FDA placed a partial clinical hold on a planned phase 2/3 study of its COVID-19 vaccine candidate INO-4800. According to Inovio, the FDA has “additional questions” about the planned trial, including the CELLECTRA 2000 delivery device to be
- Alcon Focuses on Presbyopia-Correcting IOL Innovation and the New Normal at the Virtual ESCRS 2020https://modernod.com/news/alcon-focuses-on-presbyopia-correcting-iol-innovation-and-the-new-normal-at-the-virtual-escrs-2020/2478344/Alcon will host several events and present new technologies in cataract surgery during the virtual European Society of Cataract and Refractive Surgery (ESCRS) 2020 annual meeting, taking place October 2-4. “As
- Bausch Health Announces Vyzulta Now Approved in Seven Countries; Expanded Coverage in Canadahttps://modernod.com/news/bausch-health-announces-vyzulta-now-approved-in-seven-countries-expanded-coverage-in-canada/2478323/Bausch Health Companies and Nicox announced that Vyzulta (latanoprostene bunod ophthalmic solution) 0.024% has received regulatory approval in Ukraine, bringing the total number of countries where Vyzulta is approved to market to seven. These countries include
- Rayner to Launch RayOne EMV Enhanced Monofocal IOLhttps://modernod.com/news/rayner-to-launch-rayone-emv-enhanced-monofocal-iol/2478303/Rayner has announced the upcoming European launch of RayOne EMV, a new fully preloaded non-diffractive IOL designed to enhance patient outcomes achieved with monovision. Developed in collaboration with Professor Graham Barrett, president of the Australasian Society of Cata
- Biomarker Indicating Neurodegeneration Identified in the Eyehttps://modernod.com/news/biomarker-indicating-neurodegeneration-identified-in-the-eye/2478302/A new study led by Boston Medical Center researchers indicates a well-known biomarker that serves as a marker for earlier diagnosis of neurodegenerative diseases is now detectable in the eye. Neurofilament light chain, a protein previously detected in cerebrospinal fluid and blood that is
- Study Finds Novel Mechanism That May Confer Protection Against Glaucomahttps://modernod.com/news/study-finds-novel-mechanism-that-may-confer-protection-against-glaucoma/2478298/A team of researchers from LSU Health New Orleans Neuroscience Center of Excellence and the University of Copenhagen provides the first evidence that patients with ocular hypertension may exhibit superior antioxidant protection that promotes resistance to the elevated intraocular pressure associa
- Neuro-Optometric Rehabilitation Association Announces Appointments of New Executive and Advisory Board Officershttps://modernod.com/news/neuro-optometric-rehabilitation-association-announces-appointments-of-new-executive-and-advisory-board-officers/2478297/The Neuro-Optometric Rehabilitation Association (NORA) announced the appointments of its new executive and advisory board members. DeAnn Fitzgerald, OD, assumes the position of President, succeeding Susan Daniel, OD, who now joins the NORA Advisory Board. Dr. Fitzgerald has been providing
- CEO Says Moderna Will Know by November if COVID-19 Vaccine Workshttps://modernod.com/news/ceo-says-moderna-will-know-by-november-if-covid-19-vaccine-works/2478294/
- Recordati Rare Diseases Announces Availability of Cystadrops in the UShttps://modernod.com/news/recordati-rare-diseases-announces-availability-of-cystadrops-in-the-us/2478283/Recordati Rare Diseases announced that Cystadrops (cysteamine ophthalmic solution) 0.37% is now available for prescription and distribution across the United States. Cystadrops is a new, viscous eye drop solution that depletes cystine crystal deposits in the corne
- COVID-19 Vaccine Developers Seek to Reassure Public Over Safetyhttps://modernod.com/news/covid-19-vaccine-developers-seek-to-reassure-public-over-safety/2478249/Sources suggested that a number of drugmakers, including GlaxoSmithKline, Johnson & Johnson and Pfizer, are planning to release a statement outlining their commitment to only seek FDA approval of a vaccine against COVID-19 if it is supported by extensive safety and efficacy data. The move is